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Background: This study was conducted to investigate the local effects and toxicity of accelerated hyperfractionated
intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation.
Methods: Twenty-two patients with recurrent/unresectable rectal cancer who previously received pelvic irradiation
were enrolled in our single-center trial between January 2007 and August 2012. Reirradiation was scheduled for up to
39 Gy in 30 fractions using intensity-modulated radiotherapy plans. The dose was delivered via a hyperfractionation
schedule of 1.3 Gy twice daily. Patient follow-up was performed by clinical examination, CT/MRI, or PET/CT every
3 months for the first 2 years and every 6 months thereafter. Tumor response was evaluated 1 month after reirradiation
by CT/MRI based on the RECIST criteria. Adverse events were assessed using the National Cancer Institute (NCI)
common toxicity criteria (version 3.0).
Results: The median time from the end of the initial radiation therapy to reirradiation was 30 months (range,
18-93 months). Overall local responses were observed in 9 patients (40.9%). None of the patients achieved a
complete response (CR), and 9 patients (40.9%) had a partial response (PR). Thirteen patients failed to achieve a clinical
response: 12 (54.5%) presented with stable disease (SD) and 1 (4.5%) with progressive disease (PD). Among all the
patients who underwent reirradiation, partial or complete symptomatic relief was achieved in 6 patients (27.3%)
and 13 patients (59.1%), respectively. Grade 4 acute toxicity and treatment-related deaths were not observed. The
following grade 3 acute toxicities were observed: diarrhea (2 patients, 9.1%), cystitis (1 patient, 4.5%), dermatitis
(1 patient, 4.5%), and intestinal obstruction (1 patient, 4.5%). Late toxicity was infrequent. Chronic severe diarrhea,
small bowel obstruction, and dysuria were observed in 2 (9.1%), 1 (4.5%) and 2 (9.1%) of the patients, respectively.
Conclusions: This study showed that accelerated hyperfractionated intensity-modulated radiotherapy significantly
relieved local symptoms and led to a promising local response with an acceptable toxicity profile in patients with
recurrent/unresectable rectal cancer and previous pelvic irradiation. Innovative treatment regimens should be evaluated
in future studies to improve the clinical outcome while avoiding excessive toxicity in patients with recurrent rectal
cancer and previous pelvic irradiation.
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Despite recent advances in pretreatment radiological
evaluation, total mesorectal excision, radiotherapy, and
chemotherapy, 5-10% of patients with primary rectal
cancer develop locally recurrent rectal cancer (LRRC)
[1-4]. LRRC can cause severe symptoms, including pelvic
pain, bleeding, and bowel obstruction, which signifi-
cantly impact the quality of life, and patient prognosis
remains poor [5,6]. Salvage therapy for LRRC remains a
challenge. Although radical surgery is the only approach
with a curative intent, only approximately 20-30% of pa-
tients with recurrent rectal cancer can undergo an R0 re-
section [7]. Most patients cannot undergo curative surgery
because of locally unresectable disease, lack of medical fit-
ness, an unwillingness to accept the high postoperative
morbidity and mortality rates [7], or the presence of unre-
sectable extrapelvic metastases.
Radiation is an effective approach for relieving symp-
toms and improving local control in patients with recur-
rent rectal cancer. However, some patients with recurrent
rectal cancer have previously received radiation, which in-
creases the complexity and difficulty of the management.
Reirradiation is often not recommended because of the
extremely high incidence of complications in normal tis-
sues. Although data regarding reirradiation outcomes are
scarce, several recent observations and trials have demon-
strated the safety and efficacy of reirradiation in patients
with recurrent rectal cancer who previously underwent ir-
radiation [8-13]. To reduce the potential risk of late tox-
icity in normal tissues related to previous radiation,
hyperfractionated radiation may be a good option. In
addition, NCCN guidelines recommend that intensity-
modulated radiotherapy (IMRT) be used in the context of
reirradiating patients with recurrent disease [14]. How-
ever, to the best of our knowledge, no prospective studies
have evaluated the efficacy and safety of accelerated hyper-
fractionated IMRT in patients with recurrent rectal cancer
and previous pelvic irradiation. Based on these consider-
ations, we performed a phase II study to investigate the
local effects and safety of accelerated hyperfractionated
IMRT in patients with recurrent rectal cancer who previ-
ously received pelvic irradiation.
Materials and methods
Patients
Twenty-two patients with recurrent/unresectable rectal
cancer and previous pelvic irradiation were enrolled be-
tween January 2007 and August 2012 in our single-center
trial. This prospective study was approved by our insti-
tutional review board (Fudan University Shanghai Cancer
Center), and all the patients signed informed consent
forms.
To be eligible, patients had to present with histologically
confirmed primary rectal adenocarcinoma. Each patientwas discussed, evaluated, and determined to have unresect-
able cancer by our multidisciplinary team before reirradia-
tion, and a pelvic recurrence was diagnosed by histological
confirmation or based on the typical appearance on PET/
computed tomography (CT), CT, or MRI. All the patients
had received previous pelvic irradiation. There were meas-
urable lesions in the fields of radiotherapy. The other
inclusion criteria were as follows: age between 18 and
75 years; Eastern Cooperative Oncology Group per-
formance score ≤2; adequate hematological and liver
function; leucocytes >4.0 × 109/L; platelets >100 × 109/L;
bilirubin <1.5× the upper limit of normal (ULN); aspartate
aminotransferase/alanine aminotransferase ≤2.5× ULN;
and serum creatinine <1.25× ULN.
The exclusion criteria were as follows: any other malig-
nancy; significant coronary or cardiac conditions; serious
uncontrolled infection; a psychiatric disorder; and preg-
nancy or lack of contraceptive use in women with child-
bearing potential.
Pretreatment evaluation
The pretreatment workup was performed within the two
weeks prior to initiating the reirradiation and included a
complete history, physical examination, digital rectal exam-
ination, colonoscopy (if possible), tumor biopsy (if possible),
chest CT, abdominal CT, pelvic CT or MRI or PET/CT,
and complete laboratory tests.
Radiotherapy
Radiotherapy was delivered with a linear accelerator using
6-MV photons. Each patient had a planning CT scan in
the treatment position (prone position using a belly board
or supine position). IMRT planning was performed for all
the patients based on the planning CT. Target definition
followed the recommendations of ICRU report No. 83
[15]. The target volumes and the nearby at-risk organs
were delineated on the Pinnacle 8.0 planning system. The
gross tumor volume (GTV) was determined based on a
combination of the findings from the physical exam, CT,
MRI, and/or PET/CT. The planning target volume (PTV)
was generated with a 2-3 cm margin around the GTV to
avoid as much of the bladder and small bowel as possible.
The treatment plans were optimized such that more than
98% of the PTV was completely encompassed by the 93%
isodose line while maintaining a minimum dose greater
than 90% and a maximum dose less than 110%. The small
bowel, bladder, and femoral heads were defined as at-risk
organs. The tolerances of normal tissues were defined as
follows: 1) Small bowel: No more than 180 cc above
20 Gy, no more than 65 cc above 30 Gy, and maximum
dose less than 40 Gy; 2) Femoral heads: No more than
40% volume above 25 Gy, no more than 25% volume
above 30 Gy, and maximum dose less than 40 Gy; and 3)
Bladder: No more than 40% volume above 25 Gy, no more
Table 1 Patient characteristics at primary diagnosis and



















Low anterior resection 11 50.0
Abdominoperineal resection 10 45.5






Median (Gy) 48.6 -
Range (Gy) 36-62 -
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than 40 Gy. Inverse planning with five coplanar IMRT
fields was constructed. The dose was delivered twice daily,
5 days per week, with a hyperfractionation schedule of
1.3 Gy and an interval of at least 6 h between fractions.
Thirty fractions to 39 Gy were prescribed.
Treatment after reirradiation
After reirradiation, subsequent treatment was recom-
mended as necessary but was not included in the study
protocol. Subsequent treatment (chemotherapy or surgery)
was individualized with no specific recommendations.
Study design and data evaluation
The primary endpoints of this study were local response
and symptom relief after accelerated hyperfractionated
IMRT for recurrent rectal cancer in patients with previous
pelvic irradiation. Secondary endpoints included toxicity
and follow-up.
The patients were routinely followed with clinical exam-
inations, CT/MRI, or PET/CT every 3 months for the first
2 years and every 6 months thereafter. Tumor responses
were evaluated 1 month after reirradiation by CT/MRI
according to the RECIST criteria. Adverse events were
assessed using the National Cancer Institute (NCI) com-
mon toxicity criteria (version 3.0).
The different parameters for each individual patient
were entered into a database and were analyzed using
SPSS 17.0 statistical software. Local progression-free
survival rates and overall survival rates were determined
using the Kaplan-Meier method.
Results
Patient characteristics
Twenty-two patients with recurrent rectal cancer who
previously received pelvic irradiation were enrolled be-
tween January 2007 and August 2012 in our single-center
trial. The study population had a median age of 53 years
(range, 40-68 years). Nine participants were men (40.9%),
and 13 (59.1%) were women.
Table 1 summarizes the patient characteristics at pri-
mary diagnosis and their prior treatment. The initial sta-
ging was as follows: 3 stage I patients, 2 stage II patients,
and 17 stage III patients. A total of 11 patients (50.0%)
underwent low anterior resection, 10 (45.5%) underwent
abdominoperineal resection, and 1 (4.5%) underwent local
excision. In addition, 17 patients received postoperative
chemotherapy consisting of capecitabine or 5-FU plus
oxaliplatin. Previous irradiation consisted of preoperative
irradiation in 3 patients, postoperative irradiation in 11
patients, and irradiation at first recurrence in 8 patients.
The previous radiation doses to the pelvis ranged from 36
to 62 Gy, with a median of 48.6 Gy.The patient characteristics at reirradiation are pre-
sented in Table 2. The interval between the initial sur-
gery and the first pelvic recurrence ranged from 13 to
100 months, with a median of 29 months. The median
time from the end of the initial radiation to reirradiation
was 30 months (range, 18-93 months). Four patients
with recurrent rectal cancer had simultaneous extrapel-
vic metastases at the time of reirradiation, whereas 18
patients did not present with extrapelvic metastasis.
Thirteen patients underwent reirradiation at the first re-
currence, and 9 patients underwent reirradiation at the
second recurrence. There were a total of twenty-five re-
current sites among all the patients: 20 patients had a
single site, and 2 patients had multiple sites. With re-
spect to location, 5 sites were in the perirectal region, 7
in the presacral region, 7 in the internal iliac nodal re-
gion, 5 in the perineum, and 1 in the external iliac nodal
region. After reirradiation, 18 patients received 5-FU
Table 2 Patient characteristics at reirradiation (n = 22)
Characteristics No. %
Age
Median (y) 53 -




Recurrence location (n = 25*)
Perirectal region 5 20.0
Presacral region 7 28.0
Internal iliac nodal region 7 28.0
Perineum 5 20.0
External iliac nodal region 1 4.0
Frequency of recurrence
First recurrence 13 59.1
Second recurrence 9 40.9
Reirradiation interval
Median (months) 30 -
Range (months) 18-93 -
≤2 year 7 31.8
>2 year 15 68.2
Size of largest recurrence
≤3 cm 5 22.7
>3 cm 17 77.3
CEA level
Normal (<5 ng/mL) 4 18.2







*Multiple locoregional recurrences present in 2 patients (the perirectal region
and the perineum in one patient; the presacral region, internal iliac nodal
region, and perineum in another patient).
**Subsequent chemotherapy was recommended for all patients, but 4 patients
did not undergo chemotherapy due to intestinal obstruction (2 patients),
progressive disease during reirradiation (1), and refusal (1).
Table 3 Local response rates and clinical symptom relief
Characteristics No. %
Local response
Complete response (CR) 0 0
Partial response (PR) 9 40.9
Stable disease (SD) 12 54.5
Progressive disease (PD) 1 4.5
Symptom relief*
Complete relief 6 27.3
Partial relief 13 59.1
No relief 3 13.6
*All of the patients had severe clinical symptoms before reirradiation,
including pain (17 patients), bleeding (1 patient), mass effect (1 patient), pain
and bleeding (2 patients), and bleeding and mass effect (1 patient).
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went a subsequent surgical resection.
Local response and clinical symptom relief
All the patients with recurrent rectal cancer who previ-
ously underwent pelvic irradiation were evaluated for local
responses 1 month after reirradiation using CT/MRI. In
total, 9 patients (40.9%) achieved a partial response (PR);
there was no complete response. Thirteen patients failedto achieve a clinical response, with 12 (54.5%) presenting
with stable disease (SD), and 1 (4.5%) presenting with pro-
gressive disease (PD) (Table 3).
All the patients had severe clinical symptoms before
reirradiation, including pain (17 patients), bleeding (1 pa-
tient), mass effect (1 patient), pain and bleeding (2 pa-
tients), and bleeding and mass effect (1 patient). Complete
or partial clinical symptom relief after reirradiation was
achieved in 6 patients (27.3%) and 13 patients (59.1%), re-
spectively. Clinical symptom palliation was achieved for a
median duration of 10 months (range, 3-20 months)
(Table 3).
Toxicity and dose intensity
Table 4 shows the incidence of acute toxicity during reir-
radiation. Grade 4 toxicity and treatment-related deaths
were not observed. Diarrhea was the most common side
effect. Grade 3 toxicities included diarrhea in 2 patients
(9.1%), cystitis in 1 patient (4.5%), radiation dermatitis
in 1 patient (4.5%), and an intestinal obstruction in 1
patient (4.5%).
A total of 20 patients (90.9%) received the planned
dose (39 Gy) of accelerated hyperfractionated reirradia-
tion as scheduled (mean relative dose intensity, 95.8%).
The reirradiation was terminated for 2 patients: one de-
veloped a grade 3 intestinal obstruction, and the other
experienced progressive disease. The one patient with a
grade 3 intestinal obstruction achieved symptom reso-
lution after adopting conservative treatment. Six patients
(27.3%) required a break in the reirradiation course, with
a median delay of 2 days (range, 1-6 days), due to acute
toxicity.
The incidence of late toxicity was infrequent. Only 2
patients developed severe chronic diarrhea. One patient
developed a small bowel obstruction and was hospitalized
for occasional tube decompression. Two patients devel-
oped dysuria and required percutaneous nephrostomy
drainage. None of the patients developed skin ulceration.









Diarrhea 3 (13.6) 4 (18.2) 2 (9.1) 0 (0)
Cystitis 2 (9.1) 4 (18.2) 1 (4.5) 0 (0)
Radiation
dermatitis
0 (0) 1 (4.5) 1 (4.5) 0 (0)
Intestinal
obstruction
0 (0) 0 (0) 1 (4.5) 0 (0)
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The median follow-up for all the patients after completing
the reirradiation was 17 months (range, 2-59 months). At
the time of the last follow-up, clinical local control had
been achieved in 7 patients (31.8%), and 13 patients had
developed distant metastases. The cumulative local
progression-free survival rates were 67.0% (SE, ±10.3%) at
1 year post-reirradiation and 10.7% (SE, ±9.2%) at 2 years
post-reirradiation. The median local control time was
14 months. Eighteen patients (81.8%) died, and the cumu-
lative overall survival rates were 85.9% (SE, ±7.6%) at
1 year post-reirradiation and 27.2% (SE, ±10.3%) at 2 years
post-reirradiation. The median survival time after reirra-
diation was 19 months.
Discussion
The published literature offers limited data on the use of
reirradiation for treating recurrent rectal cancer in pa-
tients with previous pelvic irradiation. To the best of our
knowledge, no previous prospective studies have evaluated
the efficacy and safety of accelerated hyperfractionated
IMRT in recurrent rectal cancer patients with previous
pelvic irradiation. This study determined whether acceler-
ated hyperfractionated IMRT is effective and safe for treat-
ing recurrent/unresectable rectal cancer in patients with
previous pelvic irradiation. The overall local response rate
was 40.9%, and the clinical symptom relief rate was 86.4%.
Grade 4 acute toxicity and treatment-related deaths were
not observed. Grade 3 diarrhea, cystitis, radiation derma-
titis, and intestinal obstruction were observed in 9.1%,
4.5%, 4.5%, and 4.5% of the participants, respectively. Late
toxicity was infrequent and mild.
Reirradiation for recurrent rectal cancer has historic-
ally been unacceptable for patients with previous pelvic
irradiation because of the extremely high incidence of
complications in normal tissues. Data on reirradiation
are scarce. However, several recent reports and trials
have demonstrated the safety and efficacy of reirradia-
tion for treating recurrent rectal cancer in patients with
previous pelvic irradiation [8,10-13]. Although a high
reirradiation dose cannot be applied to previously irradi-
ated regions, reirradiation doses of 30-40 Gy are well
tolerated and provide decent palliation in most patients.
Recently, hyperfractionated reirradiation has been usedfor recurrent rectal cancer to reduce the risk for late
toxicity in normal tissues related to previous irradiation.
Several studies have suggested that hyperfractionated
reirradiation is a valuable treatment option that provides
effective palliation with an acceptable toxicity profile
[11,12]. Additionally, to reduce toxicity in normal tis-
sues, IMRT has been recommended when reirradiating
patients with recurrent rectal cancer [14]. Several dosi-
metric and clinical studies have shown that IMRT for
rectal cancer can reduce the dose delivered to the small
bowel (thereby reducing treatment-related toxicity) com-
pared with standard 3DCRT [16,17]. Based on these
considerations, accelerated hyperfractionated IMRT was
used to treat patients with recurrent rectal cancer after
previous pelvic irradiation.
Although reirradiation concurrent with chemotherapy
may lead to better clinical outcomes, we did not evaluate
this regimen in our study. Mohiuddin et al. [10] reported
high toxicity in patients concurrently treated with reirra-
diation and continuous 5-FU infusion. In their study,
28% of the patients developed grade 3 to 4 acute toxicity
during reirradiation, and 21% of the patients developed
late complications, such as chronic severe diarrhea and
small bowel obstruction. This acute toxicity required
interrupting or terminating the treatment in 22% of the
patients. In our study, the total reirradiation course was
only 3 weeks, and the impact of concurrent chemother-
apy may have been small. Moreover, in our study, the in-
tent of reirradiating patients with inoperable recurrent
rectal cancer was palliative.
Our study achieved an overall local response rate of
40.9%. None of the patients achieved a CR, mainly due
to the large tumor sizes (77.3% of the patients had le-
sions larger than 3 cm) and the low total reirradiation
dose. These findings are comparable to those reported
in previous trials. Valentini et al. [11] reported results
from a multicenter phase II study of reirradiation in 59
patients with recurrent rectal cancer. These patients
were treated twice daily with 1.2-Gy fractions for a cu-
mulative dose of 40.8 Gy and with concurrent continu-
ous 5-FU infusion. The authors reported a 44.1% overall
response rate (CR, 8.5%; PR, 35.6%). Another retrospect-
ive study [13] investigated reirradiation in 22 patients
with recurrent rectal cancer who had previously received
pelvic irradiation. The overall response rates at 1 and
3 months were 32% and 41%, respectively. A CR was ob-
served in one patient (5%) at 3 months. The percentage of
PRs increased from 27% at 1 month to 37% at 3 months.
Reirradiation provided effective symptomatic palli-
ation, even at the lower total dose that was administered
to the recurrent rectal tumors. In our study, the clinical
symptom relief rate was 86.4% (complete symptom relief
rate, 27.3%; partial symptom relief rate, 59.1%). The pro-
portion of patients achieving clinical symptomatic relief
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studies. Mohiuddin et al. [10] reported that bleeding,
pain, and the effects of the tumor were positively impacted
in 100%, 82.6%, and 88.9% of the patients, respectively,
after reirradiation. Valentini et al. [11] also reported a high
symptom relief rate (83.3%) 4 weeks after the end of the
reirradiation and concurrent chemotherapy.
In our study, the toxicity data revealed that accelerated
hyperfractionated IMRT was well tolerated, with low
rates of acute and late toxicity, in patients with recurrent
rectal cancer and previous pelvic irradiation. Diarrhea
was the most common acute toxicity; late toxicity was
infrequent and mild. Various acute and late toxicities
have been described in the literature, and most studies
have reported a low incidence of toxicity, similar to our
results [11,13]. However, Mohiuddin et al. [10] reported
that 22% of the patients required a significant treatment
interruption, and 15% of the patients terminated treat-
ment due to severe acute toxicities. Additionally, grade 4
diarrhea was observed in 6% of the patients, and late
complications were reported for 21.4% of the patients.
Das et al. [12] also reported a high incidence of grade 3
to 4 late toxicity (26%). The incidence of reirradiation
toxicity is correlated with many factors, such as reirra-
diation dose, reirradiation fractionation, total cumulative
dose, the amount of small bowel that is exposed to the
radiation field, reirradiation intervals, and the previous
radiation and reirradiation volumes. When reirradiating
the pelvis to treat recurrent rectal cancer, every effort
should be made to limit the dose to the small bowel and
bladder in the radiation field.
Although reirradiation of recurrent rectal cancer can
result in excellent palliation of symptoms and good local
responses with acceptable toxicity, the long-term local
control and survival remain poor. To improve these factors,
other approaches, such as radiotherapy dose escalation,
radiotherapy combined with newer chemotherapeutic and
biological agents, intraoperative radiotherapy, hyperther-
mia, radical surgery, and systemic treatment, should be
investigated in future studies.
Our study had several limitations. One limitation is
that the sample size was small. Furthermore, late toxicity
may have been incompletely assessed based on medical
records. Moreover, some patients who might have devel-
oped late toxicity died prematurely. Therefore, the late
toxicity rates may have been underestimated.
In conclusion, accelerated hyperfractionated IMRT can
provide excellent symptom palliation and a good local
response in patients with recurrent/unresectable rectal
cancer and previous pelvic irradiation. The toxicity pro-
files for the dosage and schedule used in our study were
acceptable. Additional studies are necessary to develop
innovative treatment regimens and improve the clinical
outcome while avoiding excessive toxicity in patientswith recurrent rectal cancer who received previous pel-
vic irradiation.
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